New Capabilities Automatically Identify Patients for 10 High-Impact Structural Heart and Heart Failure Clinical Trials 

egnite, Inc., a leading cardiovascular digital health company announced the launch of the CardioCare Research Suite, a significant expansion of its flagship platform designed to streamline and enhance patient identification for clinical trials.

Health Technology Insights: SeqOnce Biosciences Expands Pathogen Assays with RT-qPCR Measles Panel

The CardioCare Research Suite launched to support ten landmark clinical trials in structural heart and heart failure care, including AIM-HIGHer, ALT-FLOW II, APOLLO, ARTIST, CLASP IIF, CLASP II TR, CORCINCH-HF, EMPOWER, ENCIRCLE, and PROGRESS.

The Research Suite supports ten landmark clinical trials in structural heart and heart failure care, including AIM-HIGHer, ALT-FLOW II, APOLLO, ARTIST, CLASP IIF, CLASP II TR, CORCINCH-HF, EMPOWER, ENCIRCLE, and PROGRESS.

Health Technology Insights: Telemedicine Addiction Treatment Effectively Supports Hepatitis C Care

This expansion addresses a long-standing challenge in clinical research, ensuring the right patients are surfaced at the right time for trial consideration. Through the use of AI and natural language processing to analyze both structured and unstructured hospital data, the CardioCare Research Suite empowers hospitals to expand access to novel therapies and reduce the operational burden on research teams.

Early adopters of the Research Suite have reported meaningful results:

  • Over 50% of patients identified through the platform had never been seen by the principal investigator or a relevant specialist.
  • 25%–50% of patient consents were sourced directly from CardioCare.
  • Trial coordinators report significantly less time spent identifying candidates.
  • The platform facilitates more precise, patient-focused outreach by trial investigators, addressing the complexity of evolving eligibility criteria.

“Since our inception, ambitious programs have expressed a desire to leverage the CardioCare platform to move from passive intake to proactive identification of clinical trial patients,” said Kahla Verhoef, Chief Operating Officer at egnite. “The Research Suite is a direct response to that need, empowering research teams to efficiently surface eligible patients from complex data, align with evolving trial criteria, and engage physicians with precision and confidence.”

egnite’s CardioCare Research Suite is now an available offering to all partner hospitals using the CardioCare platform. With the ability to leverage AI across structured and unstructured data, the platform uniquely equips research teams to accelerate enrollment and drive clinical innovation forward.

Health Technology Insights: Fellow Health Partners, Minset AI Partner to Transform Revenue Cycle

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – businesswire